Shares of ASLAN Pharmaceuticals rose more than 83 percent after the company announced positive preliminary data in an atopic dermatitis study.
Amgen will buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with the company’s $74 billion deal for Celgene by the end of 2019.
Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.
